Candriam S.C.A. Clovis Oncology, Inc. Call Options Transaction History

Candriam S.C.A.

  • $17.1 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding CLVS

# of Institutions
1
Shares Held
166
Call Options Held
0
Put Options Held
0
View Full List

About Clovis Oncology, Inc.

CLVS Quotes by TradingView
  • Ticker CLVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 144,480,000
  • Market Cap $13M
  • Description
  • Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...
More about CLVS
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email